Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 5, 2010, Pages 719-725

  Chen, Jinn Shiun ^a,b   Chen, Kuei Tien ^c   Fan, Wen Chun ^c   Yu, Jau Song ^c   Chang, Yu Sun ^c   Chan, Err Cheng ^c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Carcinoembryonic antigen; Colorectal cancer; Enzyme linked immunosorbent assay; Survivin autoantibody

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; SURVIVIN AUTOANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SERUM; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DATA INTERPRETATION, STATISTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; RECOMBINANT PROTEINS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77952533027     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.123     Document Type: Article

References (33)

1. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
2. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
3. Geenen JE, Schmitt MG Jr, Wu WC, Hogan WJ. Major complications of coloscopy: bleeding and perforation. Am J Dig Dis 1975;20:231-5.
4. Silvis SE, Nebel O, Rogers G, Sugawa C, Mandelstam P. Endo-scopic complications. Results of the 1974 American Society for Gastrointestinal Endoscopy Survey. J Am Med Assoc 1976;235:928-30.
5. Woolf SH. The best screening test for colorectal cancer - a personal choice. N Engl J Med 2000;343:1641-3.
6. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Mac-donald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
7. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480-7.
8. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000;60:1777-88.
9. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001;108:1411-5.
10. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003;12:136-43.
11. Koziol JA, Zhang JY, Casiano CA, Peng XX, Shi FD, Feng AC, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003;9:5120-6.
12. Yagihashi A, Asanuma K, Kobayashi D, Tsuji N, Shijubo Y, Abe S, et al. Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. Lung Cancer 2005;48:217-21.
13. Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000;60:1815-7.
14. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
15. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-4.
16. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997;16:6914-25.
17. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Olters-dorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-20.
18. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998;17:3247-59.
19. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antia-poptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998;58:1808-12.
20. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. J Am Med Assoc 2001;285:324-8.
21. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-4.
22. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-3.
23. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998;187:1163-7.
24. Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, et al. Immunity to oncogenic proteins. Immunol Rev 1995;145:33-59.
25. Douglas CA, Ellershaw J. Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer. Palliat Med 2003;17:638-9.
26. Mozo L, Simo A, Suarez A, Rodrigo L, Gutierrez C. Autoan-tibodies to Golgi proteins in hepatocellular carcinoma: case report and literature review. Eur J Gastroenterol Hepatol 2002;14:771-4.
27. Asherson RA. Antiphospholipid antibodies, malignancies and paraproteinemias. J Autoimmun 2000;15:117-22.
28. Chang JT, Wong FH, Liao CT, Chen IH, Wang HM, Cheng AJ. Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. Clin Chem 2004;50:1261-4.
29. Yagihashi A, Asanuma K, Nakamura M, Araya J, Mano Y, Torigoe T, et al. Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin Chem 2001;47:1729-31.
30. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000;46:645-50.
31. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colo-rectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003;39:718-27.
32. Roessler M, Rollinger W, Mantovani-Endl L, Hagmann ML, Palme S, Berndt P, et al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol Cell Proteomics 2006;5:2092-101.
33. Wharton RQ, Jonas SK, Glover C, Khan ZA, Klokouzas A, Quinn H, et al. Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples. Clin Cancer Res 1999;5:4158-63.